AW Tolcher, K Khan, M Ong, U Banerji, V Papadimitrakopoulou, DR Gandara, A Patnaik, RD Baird, D Olmos, CR Garrett, JM Skolnik, EH Rubin, PD Smith, P Huang, M Learoyd, KA Shannon, A Morosky, E Tetteh, Y-M Jou, KP Papadopoulos, V Moreno, B Kaiser, TA Yap, L Yan, JS de Bono
Journal name: 
Clin Cancer Res
Citation info: 
PURPOSE: KRAS is the most commonly mutated oncogene in human tumors. KRAS-mutant cells may exhibit resistance to the allosteric MEK1/2 inhibitor selumetinib (AZD6244; ARRY-142886) and allosteric AKT inhibitors (such as MK-2206), the combination of which may overcome resistance to both monotherapies. EXPERIMENTAL DESIGN: We conducted a dose/schedule-finding study evaluating MK-2206 and selumetinib in patients with advanced treatment-refractory solid tumors. Recommended dosing schedules were defined as MK-2206 at 135 mg weekly and selumetinib at 100 mg once daily. RESULTS: Grade 3 rash was the most common dose-limiting toxicity (DLT); other DLTs included grade 4 lipase increase, grade 3 stomatitis, diarrhea, and fatigue, and grade 3 and grade 2 retinal pigment epithelium detachment. There were no meaningful pharmacokinetic drug-drug interactions. Clinical antitumor activity included RECIST 1.0-confirmed partial responses in non-small cell lung cancer and low-grade ovarian carcinoma. CONCLUSION: Responses in KRAS-mutant cancers were generally durable. Clinical cotargeting of MEK and AKT signaling may be an important therapeutic strategy in KRAS-driven human malignancies (Trial NCT number NCT01021748).
E-pub date: 
15 Feb 2015
Users with this publication listed: 
Richard Baird